drugset / Trial / NCT05464173
Chidamide in Combination With Abemaciclib and Endocrinotherapy（Doctor's Choice） in Breast Cancer Patients Previously Treated With Palbociclib
NaSingle-groupOpen-labelTreatment
Summary
To evaluate the efficacy and safety of chidamide in combination with abemaciclib and endocrinotherapy（doctor's choice） in locally advanced/metastatic HR+/HER2- breast cancer who had failed prior palbociclib therapy
Timeline
- Start
- 2022-07-01
- Primary completion
- 2025-02-01
- Completion
- 2025-05-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Abemaciclib | Small molecule | 100 mg | — |
| Subject | Abemaciclib | Small molecule | 150 mg | — |
| Subject | Tucidinostat | Small molecule | 10 mg | — |
| Subject | Tucidinostat | Small molecule | 30 mg | — |